Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis
Autore:
Zarate, E; Watcha, MF; White, PF; Klein, KW; Rego, MS; Stewart, DG;
Indirizzi:
Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, Dallas, TX 75235 USA Univ Texas Dallas TX USA 75235 ol & Pain Management, Dallas, TX 75235 USA Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA Childrens Hosp Philadelphia Philadelphia PA USA 19104 lphia, PA 19104 USA
Titolo Testata:
ANESTHESIA AND ANALGESIA
fascicolo: 6, volume: 90, anno: 2000,
pagine: 1352 - 1358
SICI:
0003-2999(200006)90:6<1352:ACOTCA>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
PLACEBO-CONTROLLED TRIALS; POSTOPERATIVE NAUSEA; INTRAVENOUS DOLASETRON; SURGERY; PREVENTION; OUTCOMES; SAFETY; OUTPATIENTS; MEANINGFUL; ANESTHESIA;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
28
Recensione:
Indirizzi per estratti:
Indirizzo: White, PF Univ Texas, SW Med Ctr, Dept Anesthesiol & Pain Management, 5161harry Hines Blvd,CS2-126, Dallas, TX 75235 USA Univ Texas 5161 harry HinesBlvd,CS2-126 Dallas TX USA 75235 USA
Citazione:
E. Zarate et al., "A comparison of the costs and efficacy of ondansetron versus dolasetron for antiemetic prophylaxis", ANESTH ANAL, 90(6), 2000, pp. 1352-1358

Abstract

The optimal dose and timing of 5-HT3 antagonist administration for prophylaxis against postoperative nausea and vomiting (PONV) remains controversial. Although 5-HT3 antagonists seem to be most effective when administered near the end of surgery, there are no data on the comparative efficacy or costs associated with the 5-HT3 antagonists dolasetron and ondansetron when administered at the end of the operation. In this double-blinded study, 200 outpatients undergoing otolaryngologic procedures with a standardized general anesthetic received 4 (O4) or 8 mg (O8) of ondansetron or 12.5 (D12.5) or25 mg (D25) of dolasetron IV within 30 min before the end of surgery. A blinded observer recorded the emetic episodes, maximum nausea score, recoveryroom resource and drug use, nursing time spent managing PONV, times to achieve discharge criteria from the Phase 1 and 2 recovery units, postdischarge emesis, and patient satisfaction. Total costs were calculated by using the perspective of a free-standing surgicenter. There were no differences in patient demographics, incidence of PONV, need for rescue medications, time spent in the recovery areas, unanticipated hospital admissions, or patient satisfaction among the four treatment groups. The mean total costs (95% confidence intervals) to prevent PONV in one patient were lowest in the D12.5 group: $23.89 (17.18-28.79) vs S37.81 (30.29-45.32), $33.91 (28.92-39.35), and $75.18 (61.13-89.24) for D25, O4, and O8, respectively. Excluding nursing labor costs did not alter this finding: $18.51 (14.18-22.85), $34.77 (28.03-41.49), $31.77 (28.92-39.35), and $71.76 (58.17-85.35) for D12.5, D25, O4., and O8, respectively. We conclude that 12.5 mg of dolasetron TV is more cost effective than 4 mg of ondansetron IV for preventing PONV after otolaryngologic surgery and is associated with similar patient satisfaction.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/10/20 alle ore 01:20:01